Clinical Trial Update: Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating obinutuzumab with or without umbralisib, lenalidomide, or combination chemotherapy for relapsed or refractory Grade 1-3a folli…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Combination chemotherapy
• Lenalidomide (lenalidomide)
• Obinutuzumab (obinutuzumab)
• umbralisib

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING